Orchid Chemicals And Pharmaceuticals
Orchid Chemicals and Pharmaceuticals Ltd., commonly referred to as Orchid Pharma, is a prominent player in the Indian pharmaceutical industry, headquartered in Chennai, India. Founded in 1992, the company has established itself as a leader in the development and manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms, particularly in the areas of anti-infectives, cardiovascular, and central nervous system medications. With a strong presence in both domestic and international markets, Orchid Pharma has achieved significant milestones, including regulatory approvals from major global health authorities. The company is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that cater to various therapeutic segments. Orchid's strategic focus on research and development has positioned it as a competitive force in the pharmaceutical landscape, making it a trusted partner for healthcare providers worldwide.
DitchCarbon Score
How does Orchid Chemicals And Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Orchid Chemicals And Pharmaceuticals's score of 31 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Orchid Chemicals And Pharmaceuticals's reported carbon emissions
In 2024, Orchid Chemicals and Pharmaceuticals reported total carbon emissions of approximately 34,000 kg CO2e for Scope 1 and about 41,557,479 kg CO2e for Scope 2, resulting in a combined total of approximately 41,591,479 kg CO2e. This marks a significant reduction from 2023, where emissions were approximately 4,594,000 kg CO2e for Scope 1 and about 381,028,000 kg CO2e for Scope 2, totalling around 385,622,000 kg CO2e. Orchid has committed to achieving net-zero emissions by 2050, with targets set across all scopes. The company is actively working towards these long-term goals, having initiated its climate commitments in 2023. While specific reduction percentages have not been disclosed, Orchid is on track with its near-term targets, demonstrating a proactive approach to climate action within the pharmaceuticals sector. The company has not yet reported any Scope 3 emissions, indicating a focus on direct and indirect emissions from its operations and energy use. Orchid's efforts reflect a growing trend in the pharmaceutical industry towards sustainability and responsible environmental stewardship.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 4,594,000 | 000,000.00 |
| Scope 2 | 381,028,000 | 00,000,000.00 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Orchid Chemicals And Pharmaceuticals is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
